The Thymus and the Immune System: Layered Levels of Control

Por Lee, Diana K., Hakim, Frances T., Gress, Ronald E.
Publicado em 2010

GPC5 Gene and Its Related Pathways in Lung Cancer

Por Li, Yafei, Yang, Ping
Publicado em 2011

“Pseudo-Cavitation” in Thymic Carcinoma during Treatment with Sunitinib

Por Tiseo, Marcello, Rajan, Arun, Thomas, Anish, Giaccone, Giuseppe
Publicado em 2013

Acute Autoimmune Hepatitis, Myositis and Myasthenic Crisis in a Patient with Thymoma

Por Rajan, Arun, Kotlyar, David, Giaccone, Giuseppe
Publicado em 2013

Targeting ALK, ROS1, and BRAF kinases

Por Doebele, Robert C., Camidge, D. Ross
Publicado em 2012

A Severe Photosensitivity Dermatitis Caused by Crizotinib

Por Oser, Matthew G., Jänne, Pasi A.
Publicado no J Thorac Oncol (2014)

From Mice to Men and back – an assessment of preclinical model systems for the study of lung cancers

Por Gazdar, Adi F., Hirsch, Fred R., Minna, John D.
Publicado no J Thorac Oncol (2015)

Response to: Do mutations of the enhancer of zeste homolog 2 gene exist in small-cell lung cancer?

Por Hubaux, Roland, Thu, Kelsie L., Lam, Wan L.
Publicado em 2013

Imaging During Radiation Therapy Captures Abrupt and Dramatic Changes

Por Kong, Feng-Ming (Spring), Wong, Kakit, Ritter, Timothy
Publicado em 2012

Lazarus-type response to crizotinib in a patient with poor performance status and advanced MET exon 14 skipping mutation-positive lung adenocarcinoma

Por Shea, Meghan, Huberman, Mark S., Costa, Daniel B.
Publicado no J Thorac Oncol (2016)

Association of Early Palliative Care with Chemotherapy Intensity in Patients with Advanced Stage Lung Cancer:: A National Cohort Study

Por Lammers, A, Slatore, CG, Fromme, EK, Vranas, KC, Sullivan, DR
Publicado no J Thorac Oncol (2018)

Serum concentrations of erlotinib at a dose of 25 mg daily

Por Costa, Daniel B., Yeo, Wee-Lee, Hamada, Akinobu, Kobayashi, Susumu
Publicado em 2010

Summary of the Proceedings from the 10th Annual Meeting of Molecularly Targeted Therapy in NSCLC

Por Pal, Sumanta K., Reckamp, Karen L.
Publicado em 2010

Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer

Por Sehgal, Kartik, Peters, Mary Linton B., VanderLaan, Paul A., Rangachari, Deepa, Kobayashi, Susumu S., Costa, Daniel B.
Publicado no J Thorac Oncol (2018)

Targeting MEK for the Treatment of Non Small-Cell Lung Cancer

Por Goldman, Jonathan W., Garon, Edward B.
Publicado em 2012

Oncogenic Fusions Involving Exon 19 of ALK

Por Le, Anh T., Varella-Garcia, Marileila, Doebele, Robert C.
Publicado em 2012

Histologic transformation from adenocarcinoma to squamous cell carcinoma as a mechanism of resistance to EGFR inhibition

Por Levin, Pavel A., Mayer, Melissa, Hoskin, Sharon, Sailors, Joseph, Oliver, Dwight H., Gerber, David E.
Publicado no J Thorac Oncol (2015)

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small cell lung cancer

Por Rudin, Charles M., Hong, Kelvin, Streit, Michael
Publicado em 2013

Erlotinib response in a NSCLC patient with a novel compound G719D+L861R mutation in EGFR

Por Berge, Eamon M, Aisner, Dara, Doebele, Robert C
Publicado em 2013

Germ-Line and Somatic Presentations of the EGFR T790M Mutation in Lung Cancer

Por Prudkin, Ludmila, Tang, Ximing, Wistuba, Ignacio I.
Publicado no J Thorac Oncol (2009)